{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:44:48Z","timestamp":1789587888269,"version":"build-2803163510"},"reference-count":56,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.30762","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T15:34:46Z","timestamp":1635348886000},"page":"e2130762","source":"Crossref","is-referenced-by-count":69,"title":["Association of Sodium-Glucose Cotransporter\u20132 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes"],"prefix":"10.1001","volume":"4","author":[{"given":"Min","family":"Zhuo","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea E.","family":"Hawley","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"New England Geriatric Research, Education and Clinical Center, VA Bedford Healthcare System, Bedford, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Paik","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"New England Geriatric Research, Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily G.","family":"Bessette","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Wexler","sequence":"additional","affiliation":[{"name":"Diabetes Center, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Marcus Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Y.","family":"Tong","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"issue":"2","key":"zoi210883r1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2337\/dc19-1221","article-title":"Mortality implications of prediabetes and diabetes in older adults.","volume":"43","author":"Tang","year":"2020","journal-title":"Diabetes Care"},{"issue":"22","key":"zoi210883r2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi210883r3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi210883r4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi210883r5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi210883r6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi210883r8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2337\/dc06-1851","article-title":"The risk of hip fractures in older individuals with diabetes: a population-based study.","volume":"30","author":"Lipscombe","year":"2007","journal-title":"Diabetes Care"},{"issue":"21","key":"zoi210883r9","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1001\/jama.2011.715","article-title":"Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes.","volume":"305","author":"Schwartz","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"zoi210883r10","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.2337\/dc13-2957","article-title":"Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies.","volume":"37","author":"Liao","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi210883r11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1681\/ASN.2006050546","article-title":"Association of kidney function with incident hip fracture in older adults.","volume":"18","author":"Fried","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"zoi210883r12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/jgs.2018.66.issue-3","article-title":"Competing risks of fracture and death in older adults with chronic kidney disease.","volume":"66","author":"Hall","year":"2018","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"zoi210883r13","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/0003-4819-155-1-201107050-01001","article-title":"In the clinic: osteoporosis.","volume":"155","author":"Cotton","year":"2011","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi210883r14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"issue":"8","key":"zoi210883r15","doi-asserted-by":"publisher","first-page":"99123","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study.","volume":"3","author":"Blau","year":"2018","journal-title":"JCI Insight"},{"issue":"8","key":"zoi210883r16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","article-title":"Adverse effects of SGLT2 inhibitors on bone health.","volume":"14","author":"Blau","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"zoi210883r17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi210883r18","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021.","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"zoi210883r19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jclinepi.2012.10.004","article-title":"The validity of administrative data to identify hip fractures is high: a systematic review.","volume":"66","author":"Hudson","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"zoi210883r20","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2337\/dc12-1168","article-title":"Diabetes and risk of fracture-related hospitalization: the Atherosclerosis Risk in Communities Study.","volume":"36","author":"Schneider","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi210883r21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0895-4356(92)90047-Q","article-title":"Identification of fractures from computerized Medicare files.","volume":"45","author":"Ray","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"zoi210883r22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/M18-0567","article-title":"Fracture risk after initiation of use of canagliflozin: a cohort study.","volume":"170","author":"Fralick","year":"2019","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi210883r23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults.","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"zoi210883r24","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/pds.v28.12","article-title":"Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: an observational study of four US administrative claims databases.","volume":"28","author":"Wang","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"zoi210883r25","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1111\/dom.2018.20.issue-8","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: a nationwide population-based cohort study.","volume":"20","author":"Kim","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"25","key":"zoi210883r26","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care.","volume":"139","author":"Patorno","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"zoi210883r27","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1111\/dom.2018.20.issue-11","article-title":"Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D).","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"zoi210883r28","doi-asserted-by":"crossref","first-page":"m1186","DOI":"10.1136\/bmj.m1186","article-title":"Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.","volume":"369","author":"Pasternak","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"zoi210883r29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1210\/jc.2017-01593","article-title":"Clinical fractures among older men with diabetes are mediated by diabetic complications.","volume":"103","author":"Lee","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"zoi210883r30","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index.","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"8","key":"zoi210883r31","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study.","volume":"74","author":"Kim","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"zoi210883r32","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/gerona\/glaa150","article-title":"Updating International Classification of Diseases 9th Revision to 10th Revision of a claims-based frailty index.","volume":"76","author":"Gautam","year":"2021","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"7","key":"zoi210883r33","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/gerona\/gly054","article-title":"Comparing approaches to measure frailty in Medicare data: deficit-accumulation frailty index vs phenotypic frailty.","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"zoi210883r34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/EDE.0b013e318289dedf","article-title":"Matching by propensity score in cohort studies with three treatment groups.","volume":"24","author":"Rassen","year":"2013","journal-title":"Epidemiology"},{"issue":"25","key":"zoi210883r35","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"10","key":"zoi210883r36","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects.","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"446","key":"zoi210883r38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"zoi210883r39","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks.","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"zoi210883r40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bone.2016.10.026","article-title":"The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.","volume":"94","author":"Thrailkill","year":"2017","journal-title":"Bone"},{"issue":"1","key":"zoi210883r41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin.","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"zoi210883r42","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients.","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"zoi210883r43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bcp.12777","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?","volume":"81","author":"Luo","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"zoi210883r44","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3100","article-title":"Diabetes pharmacotherapy and effects on the musculoskeletal system.","volume":"35","author":"Kalaitzoglou","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"zoi210883r45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115197","article-title":"Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial.","volume":"132","author":"Hygum","year":"2020","journal-title":"Bone"},{"issue":"1","key":"zoi210883r46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus.","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"zoi210883r47","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00125-019-4955-5","article-title":"Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.","volume":"62","author":"Zhou","year":"2019","journal-title":"Diabetologia"},{"issue":"6","key":"zoi210883r48","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis.","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"zoi210883r49","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320961599","article-title":"Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.","volume":"11","author":"Lou","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"issue":"8","key":"zoi210883r50","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/jdi.v12.8","article-title":"Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? a pharmacovigilance real-world study.","volume":"12","author":"Zhao","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"12","key":"zoi210883r51","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/pds.v28.12","article-title":"Sodium-glucose co-transporter 2 inhibitors and the risk of fractures: a propensity score-matched cohort study.","volume":"28","author":"Adimadhyam","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi210883r52","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"zoi210883r53","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/CLEP","article-title":"Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US.","volume":"9","author":"Mues","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"5","key":"zoi210883r54","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/ckj\/sfz100","article-title":"Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing.","volume":"12","author":"Li","year":"2019","journal-title":"Clin Kidney J"},{"issue":"4","key":"zoi210883r55","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/dom.2018.20.issue-4","article-title":"Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records.","volume":"20","author":"Patorno","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"zoi210883r56","doi-asserted-by":"crossref","first-page":"l4772","DOI":"10.1136\/bmj.l4772","article-title":"Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.","volume":"366","author":"Pasternak","year":"2019","journal-title":"BMJ"},{"key":"zoi210883r7","unstructured":"Food and Drug Administration. FDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. September 9, 2015. Accessed November 12, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet"},{"key":"zoi210883r37","unstructured":"Aetion Evidence Platform. Software for real-world data analysis. 2020. Accessed September 24, 2021. http:\/\/aetion.com"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2785536\/zhuo_2021_oi_210883_1634737287.27798.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T15:34:58Z","timestamp":1635348898000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2785536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.30762","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]}}}